Related Experiment Video

Updated: Aug 7, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

[Use of pre-mixed insulins in diabetes treatment of young patients]

P Jarosz-Chobot1, E Otto-Buczkowska, B Malanowicz

  • 1Klinika Endokrynologii Dzieciecej Slaskiej AM w Katowicach.

Endokrynologia, Diabetologia I Choroby Przemiany Materii Wieku Rozwojowego : Organ Polskiego Towarzystwa Endokrynologow Dzieciecych
|June 24, 2003
PubMed

Insights

Pre-mixed insulins can be effectively administered to young children with type 1 diabetes. This approach offers a viable option for managing pediatric diabetes, especially when strict glycemic control is challenging.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Context:

  • Type 1 diabetes in pediatric populations presents unique management challenges.
  • Optimizing insulin therapy is crucial for preventing acute and chronic complications.
  • Pre-mixed insulin formulations offer a simplified dosing regimen.

Purpose:

  • To analyze the efficacy and applicability of pre-mixed insulin administration in young children with type 1 diabetes.
  • To evaluate patient outcomes and identify suitable candidates for this therapeutic approach.

Summary:

  • A study involving 46 children (aged 2.5-9 years) with type 1 diabetes investigated the use of pre-mixed insulins over a 3-year period.
  • Patients received either Novo Nordisk or Lilly pre-mixed insulin formulations for 10-38 months.
  • The study identified specific patient groups who may benefit from pre-mixed insulins, including very young children, those with stable diabetes and low insulin requirements, and non-cooperative patients.

Impact:

  • Pre-mixed insulins offer a viable alternative for managing type 1 diabetes in select pediatric populations.
  • This approach can simplify treatment regimens and potentially improve adherence.
  • Recommendations are provided for the judicious use of pre-mixed insulins in pediatric diabetes care, balancing glycemic control with safety concerns like hypoglycemia.
Abstract

More Related Videos

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)

Published on: March 14, 2019

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice06:41

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice

Published on: May 10, 2021

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...